Stereotactic radiotherapy for the treatment of acoustic neuromas

Department of Radiation Oncology and Division of Neurosurgery, David Geffen School of Medicine, University of California, 90045-6951, USA.
Journal of Neurosurgery (Impact Factor: 3.74). 11/2004; 101 Suppl 3:362-72.
Source: PubMed


The authors sought to assess the safety and efficacy of stereotactic radiotherapy when using a linear accelerator equipped with a micromultileaf collimator for the treatment of patients with acoustic neuromas.
Fifty patients harboring acoustic neuromas were treated with stereotactic radiotherapy between September 1997 and June 2003. Two patients were lost to follow-up review. Patient age ranged from 20 to 76 years (median 59 years), and none had neurofibromatosis. Forty-two patients had useful hearing prior to stereotactic radiotherapy. The fifth and seventh cranial nerve functions were normal in 44 and 46 patients, respectively. Tumor volume ranged from 0.3 to 19.25 ml (median 2.51 ml). The largest tumor dimension varied from 0.6 to 4 cm (median 2.2 cm). Treatment planning in all patients included computerized tomography and magnetic resonance image fusion and beam shaping by using a micromultileaf collimator. The planning target volume included the contrast-enhancing tumor mass and a margin of normal tissue varying from 1 to 3 mm (median 2 mm). All tumors were treated with 6-MV photons and received 54 Gy prescribed at the 90% isodose line encompassing the planning target volume. A sustained increase greater than 2 mm in any tumor dimension was defined as local relapse. The follow-up duration varied from 6 to 74 months (median 36 months). The local tumor control rate in the 48 patients available for follow up was 100%. Central tumor hypodensity occurred in 32 patients (67%) at a median of 6 months following stereotactic radiotherapy. In 12 patients (25%), tumor size increased 1 to 2 mm at a median of 6 months following stereotactic radiotherapy. Increased tumor size in six of these patients was transient. In 13 patients (27%), tumor size decreased 1 to 14 mm at a median of 6 months after treatment. Useful hearing was preserved in 39 patients (93%). New facial numbness occurred in one patient (2.2%) with normal fifth cranial nerve function prior to stereotactic radiotherapy. New facial palsy occurred in one patient (2.1 %) with normal seventh cranial nerve function prior to treatment. No patient's pretreatment dysfunction of the fifth or seventh cranial nerve worsened after stereotactic radiotherapy. Tinnitus improved in six patients and worsened in two.
Stereotactic radiotherapy using field shaping for the treatment of acoustic neuromas achieves high rates of tumor control and preservation of useful hearing. The technique produces low rates of damage to the fifth and seventh cranial nerves. Long-term follow-up studies are necessary to confirm these findings.

4 Reads
    • "Treatment modalities for vestibular schwannomas include conservative management with serial magnetic resonance (MR) imaging, microsurgery, and/or stereotactic radiosurgery (SRS)/radiotherapy.[44] The deterioration of hearing following the use of SRS as a treatment modality for vestibular schwannomas has been well documented and known.[26354647] At the level of the cochlea, current studies indicate a directly inverse correlation between cochlear radiation dose volumes and hearing preservation.[7254247] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tinnitus, a profoundly widespread auditory disorder, is characterized by the perception of sound in the absence of external stimulation. The aim of this work is to review the various surgical treatment options for tinnitus, targeting the various disruption sites along the auditory pathway, as well as to indicate novel neuromodulatory techniques as a mode of tinnitus control. A comprehensive analysis was conducted on published clinical and basic neuroscience research examining the pathophysiology and treatment options of tinnitus. Stereotactic radiosurgery methods and microvascular decompressions are indicated for tinnitus caused by underlying pathologies such as vestibular schwannomas or neurovascular conflicts of the vestibulocochlear nerve at the level of the brainstem. However, subsequent hearing loss and secondary tinnitus may occur. In patients with subjective tinnitus and concomitant sensorineural hearing loss, cochlear implantation is indicated. Surgical ablation of the cochlea, vestibulocochlear nerve, or dorsal cochlear nucleus, though previously suggested in earlier literature as viable treatment options for tinnitus, has been shown to be ineffective and contraindicated. Recently, emerging research has shown the neuromodulatory capacity of the somatosensory system at the level of the trigeminal nerve on the auditory pathway through its inputs at various nuclei in the central auditory pathway. Tinnitus remains to be a difficult disorder to treat despite the many surgical interventions aimed at eliminating the aberrant neuronal activity in the auditory system. A promising novel neuromodulatory approach using the trigeminal system to control such a bothersome and difficult-to-treat disorder deserves further investigation and controlled clinical trials.
    Surgical Neurology International 10/2011; 2(1):154. DOI:10.4103/2152-7806.86834 · 1.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Local tumor control after radiation of vestibular schwannomas (VS) is assessed by follow-up magnetic resonance imaging (MRI) of the brain. Transient increases in tumor volume on MRI due to radiation can mimic tumor progression but are related to radiation treatment effects known as “pseudoprogression”. Our study aims to determine the presence and impact of pseudoprogression in VS patients treated with fractionated stereotactic radiotherapy. Methods We analyzed 18 patients with VS treated with fractionated radiotherapy with at least 24 months of follow-up with T1-weighted gadolinium-enhanced MRIs. Mean follow-up time was 42 months. Pre- and post-treatment tumor volumes were calculated using OsiriX® software. Events were defined as volume changes ≥10 %. Results Tumor control rate was 94 %. Forty-four percent of tumors demonstrated increases in volume on follow-up, but all but one patient had transient increases in volume with subsequent regression. Mean tumor volume increased by 35 % with the average time to regression of 24 months. Adverse side effects were more frequent in patients demonstrating pseudoprogression. There were no differences in outcomes based on pre-treatment tumor size or cystic-type versus solid-type tumors. Conclusions Fractionated stereotactic radiation therapy is an effective treatment for VS. Follow-up imaging with T1-weighted gadolinium-enhanced MRI demonstrated pseudoprogression in a third of patients occurring up to 36 months post-treatment before regression. Therefore, repeat imaging and clinical follow-up of VS should be done to rule out pseudoprogression and avoid unnecessary salvage treatment.
    03/2012; 2(1). DOI:10.1007/s13566-012-0084-1
  • Source
Show more